Ara
Toplam kayıt 17, listelenen: 11-17
Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data
(American Society of Hematology, 2022)
Abstract INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T
cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response ...
Comparison of efficacy and safety of generic plerixafor vs original plerixafor in the mobilization of myeloma patients
(American Society of Hematology, 2022)
Introduction The commonest indication for an Autologous Stem Cell Transplantation (ASCT) is still Multiple Myeloma. A successful mobilization of hematopoietic stem cells (HSC) is a sine qua non of ASCT. The introduction ...
Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort
(American Society of Hematology, 2022)
Treatment free remission (TFR) is one of the main goals of therapy in Chronic Myeloid Leukemia (CML). Patient perspective and expectations have an indicative effect on discontinuation decisions. We analyzed 116 CML patients' ...
Isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: Updated safety run-in results from the randomized phase 3 ithaca study
(American Society of Hematology, 2022)
Background: Results from a randomized, Phase 3 study by the Spanish Myeloma Group (PETHEMA/GEM) previously showed that treatment with lenalidomide plus dexamethasone (Rd) may delay progression to active disease in patients ...
Retrospective analysis of Turkish AML registry database, on behalf of AML working group of Turkish society of hematology
(American Society of Hematology, 2022)
Abstract Introduction: To investigate the demographics and treatment details of the acute myeloid leukemia (AML) patients who were diagnosed and followed up in Turkey. Methods: Patients who were recorded on the database ...
A case series of CML patients who were presented with isolated thrombocytosis
(American Society of Hematology, 2022)
Per WHO 2016 and 2022 (5th ed.) myeloproliferative disease guidelines, Chronic Myeloid Leukemia (CML) is classified under two major groups according to the presence of bcr-abl translocation; these groups require different ...
Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data
(Kare Publishing, 2022)
OBJECTIVE: Acute myeloid leukemia (AML) is a hematological malignancy that frequently affects elderly population. With introducing the hypomethylating agents (HMAs) in elderly AML treatment, survival rates and quality of ...